IMM40H exhibited stronger ADCC activity against cells associated with hematological malignancies (Raji, U266B1, Daudi, and Jeko-1 cell lines) compared to competing CD70 mAbs, while also exhibiting potent killing effects against solid tumor cells (A498) (Figures 5A, B, Supplementary Figures 5A-C). This evidence concerns the gene CD70 and hematologic disorder.